Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.